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Abstract
Background:  Co-infection with hepatitis B (HBV) and hepatitis D (HDV) is common among human immunodeficiency virus 
(HIV) infected individuals in developing countries and it aggressively accelerates progression of  liver disease to cirrhosis and 
other complications. There is scarcity of  data on HDV in sub-Saharan Africa .We investigated the sero-prevalence and factors 
associated with HDV antibody among HIV/HBV co-infected patients attending a large urban HIV clinic in Uganda.
Methods: We screened 189 HIV/HBV co-infected individuals for anti-HDV immunoglobulin G (IgG) and performed logistic 
regression to determine the associated factors. Socio-demographic, clinical data, immunological status, and liver fibrosis (as de-
termined by the Aspartate transaminase to platelet ratio index and transient elastography) were included.   
Results: Participants were predominately young and of  sound immunologic status (median age 40 years, median CD4 440 
cells/µl). 98% were on ART regimens containing anti-HBV active medications (95.2% were on TDF/3TC while 4.8% on 3TC 
containing regimen). Median duration on ART was 36 months (IQR 22-72). Anti-HDV was detected in 6/198, 3.2% (95% CI 
1.14-6.92%), associated with male gender and a duration of  more than 5 years since HIV diagnosis.
Conclusions: The sero-prevalence of  HDV antibodies among the HIV/HBV co-infected patients is low in a Ugandan urban 
cohort.
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Introduction
Hepatitis delta virus (HDV) is a defective virus and de-
pends on the hepatitis B surface antigen (HBsAg) for 
its existence1-3. Worldwide approximately 15-20 million 
people have been exposed to HDV infection, which ap-
proximately represents 5% of  the population of  chron-
ic hepatitis B.. Hepatitis D virus infection results in the 
most aggressive form of  chronic viral hepatitis especially 
in HIV infected persons4,5. Triple infection with HDV/
HBV and human immune deficiency virus (HIV) is 
common due to shared modes of  transmission; mainly 
through unprotected sexual intercourse and exposure to 
contaminated blood products6,7. Current treatment op-
tions for HIV/HBV have a limited effect on HDV in-
fection  therefore not be adequate if  there is HDV co- 
infection as response to HDV will not be achieved and 
liver disease progression continues to occur8-12.  There is 
scarcity of  data on HDV in Uganda. To the best of  our 
knowledge there has only been one study which report-
ed HDV antibody prevalence of  30.6 % in the HBsAg 
positive population and 3.1 % in the general population 
in the Northern part of  Uganda13. The aim of  this study 
was to measure the prevalence and to ascertain the fac-
tors associated with hepatitis D antibodies among HIV/
HBV co-infected adults  individuals in Uganda. 
 
Methods
This cross sectional study was performed at the Infec-
tious Diseases Institute clinic (IDI), Makerere University, 
Uganda located within Mulago Hospital complex.  Ever 
since it was opened in 2002, this clinic has registered over 
10,000 individuals of  whom 8,300 are active and are re-
ceiving ART. Over the last two years, routine screening 
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of  HIV-infected clients for hepatitis B virus has been 
ongoing and there 250 HIV/HBV co-infected patients 
attending the IDI clinic.     
 
Between September 2015 and February 2016, we were 
able to recruit 189 participants. Those that provided writ-
ten informed consent had their CD4 T-cell count, clinical 
history relevant to HIV and HBV diagnosis and medi-
cation use focusing on ART abstracted from the clinic 
records. This information was supplemented by a data 
collection tool that captured socio demographic charac-
teristics and risk factors of  HDV transmission.  Partic-
ipants had a physical examination focusing on liver dis-
ease and a complete blood count and liver enzyme assays 
done. In addition, all the participants underwent liver 
fibrosis assessment using non-invasive approaches; the 
Aspartate transaminase to platelet ratio index (APRI) and 
transient elastography with the aim of  comparing liver 
disease severity between the HDV and non HDV infect-
ed. We defined liver fibrosis as an APRI score of  ≥ 1.5 
and transient elastography score of  ≥ 9 kpa. Serum was 
tested for HDV IgG antibodies using the HDV IgG ELI-
SA assay kit (AccuDiag™ HDV-IgG ELISA, Diagnostic 
automation, inc. Woodland Hills, CA 91367, USA). The 
manufacturer reports 100% sensitivity and specificity for 
detecting HDV IgG antibodies using this test.
The study obtained ethical approval from Department 
of  Medicine, School of  Medicine Research and Ethics 
Committee (SOMREC), Makerere University, College of  
Health Sciences and the IDI scientific review committee.
 
Statistics
Data collected was analyzed using STATA software pack-
age version 11. Logistic regression was performed to de-
termine the factors associated with anti-HDV.  A P-value 
of  < 0.05 was considered to be significant.
 
Results
A convenient sample of  189 HIV/HBV co-infected pa-
tients was recruited. The study population was composed 
mainly of  young individuals; median age of  40 (IQR 33-
46) years and of  sound immunological status (median 
CD4 440 (IQR 155-590 cells/yl). Ninety-eight percent 
were on ART regimens that contained anti-HBV active 
medication (95.2% were on TDF/3TC while 4.8% on 
3TC containing regimen, 2% were not on ART). Medi-
an duration on ART was 36 months (IQR 22-72). The 
majority (56%) had documented HIV infection for more 
than 5 years and over two-thirds had been diagnosed with 
HBV co-infection at least two years prior to this study 
(table 1).  
The prevalence of  hepatitis delta antibody was 3.2% (95% 
Table 1 
Baseline characteristics of the HIV/hepatitis B co-infected patients at IDI clinic,  
Uganda, (N=189). 
 
Characteristic N=189 (%) 
Gender  
     Female 80 (42.3%) 
     Male 109 (57.7%) 
Median age (IQR) years 40(IQR 33-46) 
Age categories  
     20-30 37 (19.7%) 
     31-45 103 (54.8%) 
     45+ 
  
ON ART 
      Yes  
       No 





ART regimen   
     TDF/3TC 95.2% 
     3TC   
  




        
Median baseline  CD4 count (IQR), cells/µl 
Median current CD4 count (IQR), cells/µl* 
155(46-328) 
440(155-590) 
    
    
Median current viral load (IQR) ,copies/ml)** 20 (20-75) 
  
Time since HIV diagnosis 
 
     ≤5 years 82(43.8%) 
     >5 years 105(56.2%) 
Time since HBV diagnosis   
     ≤1 years 73(39%) 
     ≥1 years 114(61%) 
*Current CD4 results was available for  188 patients 
** Current HIV viral load was available for 174 patients 
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confidence interval 1.42-6.92%). All the participants that 
tested positive for hepatitis delta antibodies were male. 
They had been diagnosed with HIV and started on ART 
at least five years prior to this study (table 2).
The liver enzyme levels (ALT,AST),  and the platelet 
count did not significantly differ among the individuals 
with positive or negative for anti-HDV, neither was there 
a difference in the HIV viral load and CD4 T-cell count 
among individuals in these categories.   
Furthermore, there was no evidence of  liver fibrosis 
among the individuals that tested positive for anti HDV 
antibody (normal APRI SCORE (< 1), and 5/6 had a 
transient elastography score of  <7 kpa). One of  the par-
ticipants had invalid fibroscan test. Among the HDV 
negative participants, liver fibrosis was present in 5 % by 
the APRI score and 20 % by transient elastography score.
 
Discussion
Our study demonstrated a prevalence of  hepatitis delta 
antibodies in HIV/HBV co infected patients in an urban 
HIV clinic in Uganda of  3.2%. These results are compa-
rable to some other studies in sub-Saharan Africa (SSA) 
done in similar settings14-16 but quite different in other se-
lected sub-populations including those with chronic liver 
disease in West Africa where a high  anti-HDV prevalence 
ranging from  12.2 to 81.7% was documented17. Also oth-
er studies in Africa have showed varying prevalence rates 
of  HDV ranging from 0-50% in different countries18-20. 
Similarly in the developed countries, high anti-HDV 
prevalence’s of  10-15% have been documented in recent 
studies1,21,22. Reasons for the variations in the prevalence 
of  HDV exposure or infection are not clear. This could 
be a result of  modes of  transmission whereby in some 
of  these countries there could be higher rates of  IVD 
use21,22.
In addition, we have confirmed earlier findings that male 
gender was significantly associated with anti HDV anti-
body positivity23,24.
Within the limits of  small numbers in our study, we ob-
served that living with HIV for five or more years was 
also significantly associated with HDV antibodies despite 
anti retro viral (ART) use. This data may suggest that 
ART may not affect HDV antibodies however a larger 
study is required to assess the impact of  ART on HDV 
infection8.  However, HIV may increase the risk of  HDV 
acquisition since immunosuppressive states increase the 
likelihood of  chronic hepatitis B which serves as a buffer 
to hepatitis D acquisition. 
This study did not demonstrate significant differences 
in the liver fibrosis scores among the HDV negative and 
positive patients, which is in agreement with the clinical 
and laboratory data that did not suggest that individu-
als with detectable anti-HDV had a chronic liver disease. 
However, it may also be possible that the results reflect 
false positive test for HDV since no confirmation was 
made using HDV viral loads. On the other had it could 
also be a result of  resolved infection. These have been 
demonstrated in others studies as well in African set-
tings14.
Limitations
Our study has some limitations. We used a convenient 
sample of  HIV/HBV co-infected individuals that we 
could access.  The few numbers of  anti HDV antibody 
positive individuals identified in this study limited our 
ability to ascertain the factors associated with triple in-
fection. However, given that similar findings had been 
recorded elsewhere in East Africa, our findings are like-
ly to be valid. Furthermore, we were unable to perform 
HDV RNA to confirm current hepatitis delta infection 
and hence this study was based on HDV exposure and 
not necessarily current infection.
Conclusion 
The sero prevalence of  HDV antibodies among the HIV/
HBV co-infected patients is very low in a Ugandan ur-
ban cohort as compared with developed countries where 
intravenous drug use is common. Routine screening for 
anti-HDV among individuals with HIV/HBV co-infec-
tion in this setting may not be cost effective, however 
in absence of  a known etiology, targeted testing can be 
done for patients with liver disease if  not improving or 
developing liver disease while on a tenofovir based-ART 
regimen.  
Following this pilot, a larger study in which HDV-RNA 
testing is performed is recommended to assess with bet-
ter accuracy the magnitude of  HDV infection in Uganda. 
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